Jefferies Upgrades Vivus (VVUS) to Hold
Tweet
Share
E-mailGet Alerts VVUS Hot Sheet
Price: $0.47 --0%
Rating Summary:
3 Buy, 6 Hold, 4 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 0 | Down: 0 | New: 0
Rating Summary:
3 Buy, 6 Hold, 4 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 0 | Down: 0 | New: 0
Join SI Premium – FREE
Jefferies upgraded Vivus (NASDAQ: VVUS) from Underperform to Hold with a price target of $31.00 (from $9.00).
The firm comments, "The FDA approved Qsymia (formerly Qnexa), which we see as a major win for VVUS. The label and REMS contains surprises, which include physician registration and a more complex titration regimen. Although some questions remain on commercial challenges, we are positive on the initial sales trajectory and have added a partnership to our model and revised our estimates to account for increased duration."
For an analyst ratings summary and ratings history on Vivus click here. For more ratings news on Vivus click here.
Shares of Vivus closed at $26.46 yesterday.
The firm comments, "The FDA approved Qsymia (formerly Qnexa), which we see as a major win for VVUS. The label and REMS contains surprises, which include physician registration and a more complex titration regimen. Although some questions remain on commercial challenges, we are positive on the initial sales trajectory and have added a partnership to our model and revised our estimates to account for increased duration."
For an analyst ratings summary and ratings history on Vivus click here. For more ratings news on Vivus click here.
Shares of Vivus closed at $26.46 yesterday.
Create E-mail Alert Related Categories
UpgradesRelated Entities
Jefferies & CoSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
